Analysis of the effectiveness of Rucaparib in the treatment of ovarian cancer

Rucaparib (Rucaparib) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor, mainly used to treat patients with advanced ovarian cancer who carry BRCA1 or BRCA2 gene mutations. PARP inhibitors block the repair pathway of DNA single-strand breaks, making BRCA-mutated tumor cells unable to effectively repair DNA damage, thereby inducing cell death. This mechanism allows rucapanib to show significant efficacy in patients with BRCA mutation-positive ovarian cancer, especially those who have received multiple lines of chemotherapy and whose disease has progressed.

Clinical trial data show that rucapanib exhibits considerable anti-tumor effects in patients with advanced refractory ovarian cancer. In BRCA mutation-positive patients who have received at least two chemotherapy regimens, rucaparib generally has an objective response rate (ORR) of between 30% and 40% and can significantly extend progression-free survival (PFS). This means that during treatment, the patient's condition is controlled and tumor growth is effectively inhibited, thereby bringing patients longer disease remission and improved quality of life. For patients with wild-type BRCA genes or other DNA repair defects, rucapanib also showed certain efficacy, but the overall response rate was slightly lower than that of BRCA mutation-positive patients.

The therapeutic advantages of rucapanib are not only reflected in its efficacy, but also include its convenience of oral administration and relatively controllable safety. In clinical practice, patients are often able to take oral medications at home without frequent hospitalization, which significantly improves patients' medication compliance and quality of life. At the same time, doctors will develop an individualized dosage plan based on the patient's weight, liver and kidney function, and previous treatment to maximize the drug's efficacy while reducing the risk of side effects. Common adverse reactions include fatigue, nausea, abnormal hematological indicators, etc., but most patients can tolerate it and can effectively manage it through dose adjustment or symptomatic treatment.

Reference materials:https://www.drugs.com/mtm/rucaparib.html